UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		_															
Name and Address of Reporting Person * Felix Lourdes					2. Issuer Name and Ticker or Trading Symbol BioCorRx Inc. [BICX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner						
(Last) (First) (Middle) 2390 EAST ORANGEWOOD AVENUE, SUITE 575					3. Date of Earliest Transaction (Month/Day/Year) 09/30-06:00/2019							X Officer (give title below) Other (specify below) CFO and COO							
ANAHE	IM, CA 92	(Street)		4. If A	Amendn	nent,	Date	Origin	nal File	ed(Month	n/Day/Year)		_X_ Form fil	ed by One Repo	Group Filing orting Person one Reporting		pplicable l	Line)	
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
(Instr. 3)			Date (Month/Day/Year)	Exection Execution Executi			(Instr. 8)		(A) or Disposed o		of (D)	Beneficia Reported	nt of Securities ally Owned Following I Transaction(s)		Form:	rship of B	7. Nature of Indirect Beneficial		
				(Month/Day/Year)			ode	V	V Amount (A) or Pr		Price	(Instr. 3 a				wnership nstr. 4)			
7 1		09/30- 06:00/2019				A	<u>(1)</u>		1,587	A	\$ 0 29,004			D					
			Table II -					quire	the fo d, Dis	rm dis	splays a o	currei eficial	ntly valid		spond unle trol numbe				
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	3A. Deemed Execution Day any	4. Transaction Code Year) (Instr. 8)		tion	5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Und Secu	itle and ount of erlying irities rr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	y De Se Di or n(s) (I)	vnership rm of rrivative curity: rect (D) Indirect	Beneficia Ownersh (Instr. 4)		
					Code	V	(A)	(D)	Date Exerci	isable	Expiration Date	Title	or Number of Shares						
Repor	ting O	wners																	

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Felix Lourdes 2390 EAST ORANGEWOOD AVENUE SUITE 575 ANAHEIM, CA 92806	X		CFO and COO			

Signatures

/s/ Lourdes Felix	10/09-06:00/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$3.15.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.